EGFR and neoplasm: Noteworthy, PDO-33.3 displayed the lowest sensitivity to Lapatinib as single agent (IC50 = 1.3μM; Fig. S7a), suggesting that concomitant CDK12/13 inhibition may overcome an intrinsic resistance of this specific tumor to EGFR inhibition.